A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women

Osteoporosis International

Volumn 11, Issue 2, 2000, Pages 177-187

  Delmas, P D ^a   Confavreux, E ^a   Garnero, P ^a   Fardellone, P ^b   De Vernejoul, M C ^c   Cormier, C ^d   Arce, J C ^e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d université Paris Cité   (France)

^e NOVO NORDISK A S   (Denmark)

Author keywords

17 estradiol; Biochemical bone markers; Bone mineral density; Norethisterone acetate; Postmenopausal osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; NORETHISTERONE ACETATE; OSTEOCALCIN; PYRIDINOLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; URINE LEVEL;

EID: 0034066108     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004180     Document Type: Article

References (30)

1. Peck WA, Burckhardt P, Christiansen C, et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Poór G, Atkinson EJ, O'Fallon WM, Melton LJ. Determinants of reduced survival following hip fracture in men: a controlled, population-based study. Clin Orthop 1995;319:260-5.
3. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
4. Richelson LS, Wahner HW, Melton LJ III, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311:1273-5.
5. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss: a prospective study of premenopausal, perimenopausal, and postmenopausal women. J Clin Invest 1996;97:14-21.
6. Ravn P, Rix M, Andreasen H, Clemmesen B, Bidstrup M, Gunnes M. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 1997;60:255-60.
7. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
8. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28-31.
9. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169-74.
10. Naessén T, Persson I, Adami H-O, Bergström R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
11. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
12. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
13. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
14. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
15. Munk-Jensen N, Nielsen SP, Obel EB, Eriksen PB. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. BMJ 1988;296:1150-2.
16. Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
17. Nielsen SP, Bärenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol 1994;101:319-24.
18. Eiken P, Nielsen SP, Kolthoff N. Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol 1997;104:702-7.
19. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479-88.
20. Christiansen C, Nilas L, Riis BJ, Rødbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;II: 800-1.
21. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
22. Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41.
23. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1995;20:91-9.
24. Hammond CB. Women's concerns with hormone replacement therapy: compliance issues. Fertil Steril 1994;6(Suppl 2):S157-60.
25. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994;21:219-29.
26. Bærug U, Winge T, Nordland G, Faber-Swensson E, Heldaas K, Norling B, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219-28.
27. Stadberg E, Mattsson L-Å, Uvebrant M. 17β-Estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23:31-9.
28. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
29. Delmas PD, Garnero P. Utility of biochemical markers of bone resorption in osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. New York: Academic Press, 1996:1075-88.
30. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990;70:920-4.